The Failure Of Biosimilars In The US: ‘Headline’ News
• By Michael McCaughan
The Washington Post doesn't seem to appreciate the difference between biosimilars and generics, underscore the challenges facing the pathway in general.
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
